drugset / Trial / NCT05831462
De-escalation of Ticagrelor in Post PPCI
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary objective: to evaluate the efficacy and safety of De-escalation to lower dose Ticagrelor (60 mg BID) plus Aspirin (75 mg OD) versus continuation of standard dose Ticagrelor (90 mg BID) plus Aspirin (75 mg OD), 1 month after primary PCI for STEMI, in diabetic patients. Secondary objectives: To compare tolerability and discontinuation of Ticagrelor in both doses. To compare the 1ry safety \& efficacy endpoints in subgroups with different thrombotic/ischemic risk
Timeline
- Start
- 2023-06-01
- Primary completion
- 2024-03-31
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ticagrelor | Small molecule | 60 mg | — |
| Subject | Ticagrelor | Small molecule | 90 mg | — |
Indications
No indication recorded.